Bristol Myers Squibb to Advance AI Infrastructure in Collaboration with Nvidia
By Connor Hart
Bristol Myers Squibb said it will expand its partnership with Nvidia, advancing its artificial-intelligence infrastructure to increase both computational power and efficiency.
The biopharmaceutical company on Monday said it will deploy Nvidia DGX Vera Rubin NVL72 systems across its stack.
The new architecture is expected to deliver up to 10 times greater performance per megawatt than its predecessor, enabling Bristol Myers to pursue larger and more sophisticated AI workloads without increasing energy consumption.
The company said the new infrastructure will help to scale its proprietary AI models, compress discovery timelines and advance its vision of what it called collaborative hybrid intelligence. This is where AI scientists work alongside researchers to pursue first- and best-in-class medicines.
Bristol Myers said its latest investment builds on nearly three years of collaboration with Nvidia, as well as marks the next step in scaling the company's AI-driven scientific programs across oncology, hematology, cardiovascular, immunology and neuroscience.
"BMS has made a deliberate bet on AI, and we are beginning to see it pay off in our pipeline and operations," Chief Digital and Technology Officer Greg Meyers said.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
July 20, 2026 08:30 ET (12:30 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for October
Undervalued by 15%, This Utilities Stock Could Be an Unexpected AI Winner
The Thrilling 37
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
United States